Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.

You may also be interested in...

Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings

The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.

Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?

With GlaxoSmithKline and Human Genome Sciences agreeing to a merger July 16, the key question for the multinational pharma becomes what it will do to strengthen sales for Benlysta, a lupus drug launched in 2011 that has fallen short of bullish commercial expectations.

Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?

Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts